Benign multiple sclerosis (MS) is a discussed clinical entity, with variable reported prevalence (6–64%) requiring at least 5–10 years of clinical observation. Moreover, many benign patients progress with time becoming no longer benign (NLB). The objective of this study is to compare benign MS patients (EDSS ≤3, 10 years from disease onset) who still fulfilled the definition at 20 years to those NLB. In our retrospective study based on Ottawa Hospital MS Clinic database, 175 benign patients fulfilled the inclusion criteria (clinically definite MS, EDSS ≤3 at 10 years, disease onset from 1983 to 1993, and clinical assessments performed at 10 ± 1 and 20 ± 1 years from onset). Out of the identified patients, 66.3% remained benign at 20 years; however, by changing the definition for benign to EDSS ≤2 or ≤1 at 10 years, they increased to 71.9 and 81.6%, respectively. Female sex, EDSS ≤1 at 10 years, and a pure sensory onset were associated with a benign course, while a pure motor onset with an NLB condition. According to multivariate analysis, an EDSS ≤2 at 10 years predicted a long-term benign course. Our study questions the current definition of “benign” MS, suggesting a more stringent EDSS cutoff at 10 years to predict long-term benign prognosis.
This is a preview of subscription content, log in to check access.
Compliance with ethical standards
Conflicts of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
This study has been performed in accordance with the Declaration of Helsinki and with the ethical standards of the institution.
McAlpine D (1961) The benign form of multiple sclerosis. A study based on 241 cases seen within 3 years of onset and followed up until the tenth year or more of the disease. Brain 84:186–203CrossRefPubMedGoogle Scholar
Kurtzke JF, Beebe GW, Nagler B et al (1977) Studies on the natural history of multiple sclerosis VIII. Early prognostic features of the later course of the illness. J Chron Dis 30:819–830CrossRefPubMedGoogle Scholar
Poser S, Wikström J, Bauer HJ (1979) Clinical data and the identification of special forms of multiple sclerosis in 1271 cases studied with a standardized documentation system. J Neurol Sci 40:159–168CrossRefPubMedGoogle Scholar
Thompson AJ, Hutchinson M, Brazil J et al (1986) A clinical and laboratory study of benign multiple sclerosis. QJM 225:69–80Google Scholar
Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907–911CrossRefPubMedGoogle Scholar
Ramsaransing GS, De Keyser J (2006) Benign course in multiple sclerosis: a review. Acta Neurol Scand 113:359–369CrossRefPubMedGoogle Scholar
Ramsaransing GSM, De Keyser J (2007) Predictive value of clinical characteristics for benign multiple sclerosis. Eur J Neurol 14:885–889CrossRefPubMedGoogle Scholar
Sayao AL, Devonshire V, Tremlett H (2007) Longitudinal follow-up of “benign” multiple sclerosis at 20 years. Neurology 68:496–500CrossRefPubMedGoogle Scholar
Costelloe L, Thompson A, Walsh C et al (2008) Long-term clinical relevance of criteria designating multiple sclerosis as benign after 10 years of disease. J Neurol Neurosurg Psychiatry 79:1245–1248CrossRefPubMedGoogle Scholar
Glad SB, Nyland HI, Aarseth JH et al (2009) Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway. Mult Scler 15:942–950CrossRefPubMedGoogle Scholar
Leray E, Coustans M, Le Page E et al (2013) ‘Clinically definite benign multiple sclerosis’, an unwarranted conceptual hodgepodge: evidence from a 30-year observational study. Mult Scler 19:458–465CrossRefPubMedGoogle Scholar
Pittock SJ, McClelland RL, Mayr WT et al (2004) Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann Neurol 56:303–306CrossRefPubMedGoogle Scholar
Hirst C, Ingram G, Swingler R et al (2008) Change in disability in patients with multiple sclerosis: a 20-year prospective population-based analysis. J Neurol Neurosurg Psychiatry 79:1137–1143CrossRefPubMedGoogle Scholar
Jacobs LD, Beck RW, Simon JH et al (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343:898–904CrossRefPubMedGoogle Scholar
Comi G, Filippi M, Barkhof F et al (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet 357:1576–1582CrossRefPubMedGoogle Scholar
Kappos L, Polman CH, Freedman MS et al (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndrome. Neurology 67:1242–1249CrossRefPubMedGoogle Scholar
Comi G, Martinelli V, Rodegher M et al (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374:1503–1511CrossRefPubMedGoogle Scholar
Freedman MS, Comi G, De Stefano N et al (2014) Moving toward earlier treatment of multiple sclerosis: findings from a decade of clinical trials and implications for clinical practice. Mult Scler Relat Disord 3:147–155CrossRefPubMedGoogle Scholar
Freedman MS (2013) Present and Emerging Therapies for Multiple Sclerosis. Continuum (Minneap Minn) 19:968–991Google Scholar
Oh J, O’Connor PW (2015) Novel and imminently emerging treatments in relapsing-remitting multiple sclerosis. Curr Opin Neurol 28:230–236CrossRefPubMedGoogle Scholar
Poser CM, Paty DW, Scheinberg L et al (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227–231CrossRefPubMedGoogle Scholar
Polman CH, Reingold SC, Edan G et al (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 58:840–846CrossRefPubMedGoogle Scholar
Joseph FG, Hirst CL, Pickersgill TP et al (2009) CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients. J Neurol Neurosurg Psychiatry 80:292–296CrossRefPubMedGoogle Scholar
Portaccio E, Stromillo ML, Goretti B et al (2009) Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis. Neurology 73:498–503CrossRefPubMedGoogle Scholar
Perini P, Tagliaferri C, Belloni M et al (2001) The HLA-DR13 haplotype is associated with benign multiple sclerosis in northeast Italy. Neurology 57:158–159CrossRefPubMedGoogle Scholar
Amato MP, Zipoli V, Goretti B et al (2006) Benign multiple sclerosis: cognitive, psychological and social aspects in a clinical cohort. J Neurol 253:1054–1059CrossRefPubMedGoogle Scholar
Calabrese M, Favaretto A, Poretto V et al (2013) Low degree of cortical pathology is associated with benign course of multiple sclerosis. Mult Scler 19:904–911CrossRefPubMedGoogle Scholar